Zobrazeno 1 - 10
of 12
pro vyhledávání: '"H. A. Chaudri-Ross"'
Autor:
Ashley Kang, Meghan Jensen, Suhail M. Ali, Allan Lipton, Walter P. Carney, Jaqueline Willemann Rogerio, Kim Leitzel, Nicholas Bade, David Chen, Raymond Hall, H. A. Chaudri-Ross, Scott Hofsess, Ashwani Garg
Publikováno v:
Cancer Research. 75:P3-06
Introduction: The prognostic and predictive utility of pretreatment serum activin A (TGF-B superfamily ligand) was correlated with the response of first-line metastatic breast cancer patients (MBC) in the phase 3 randomized trial of letrozole vs. tam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c94e9ffec8519dc53bf1acc0260f84bf
https://doi.org/10.1158/1538-7445.sabcs14-p3-06-14
https://doi.org/10.1158/1538-7445.sabcs14-p3-06-14
Autor:
Kim Leitzel, Karen Pierce, H. A. Chaudri-Ross, Allan Lipton, Dean B. Evans, Laurence M. Demers, Suhail M. Ali, Victor Gaur, Peter J. Hamer, Sheryl Brown-Shimer, Walter P. Carney
Publikováno v:
Journal of Clinical Oncology. 26:2653-2658
PurposeTo determine the effect of elevated serum TIMP-1 on the response of patients with metastatic breast cancer to an aromatase inhibitor versus tamoxifen.Patients and MethodsFive hundred twenty-two patients estrogen receptor–positive metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022b8e1711b5bcbb52d4555d04a7f9b9
https://doi.org/10.1200/jco.2007.15.4336
https://doi.org/10.1200/jco.2007.15.4336
Autor:
H. Mouridsen, D. Becquart, R. Lang, Yongkun Sun, H. A. Chaudri-Ross, M. Gershanovich, R. Perez-Carrion
Publikováno v:
The Oncologist. 9:489-496
Learning Objectives After completing this course, the reader will be able to: Identify which advanced breast cancer patients in the three subsets studied (with nonvisceral metastases, with visceral metastases without liver involvement, and with liver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4c48ad6d27d1fc8b86fb16ec171850
https://doi.org/10.1634/theoncologist.9-5-489
https://doi.org/10.1634/theoncologist.9-5-489
Autor:
H. Mouridsen, H. A. Chaudri-Ross
Publikováno v:
The Oncologist. 9:497-506
Learning Objectives After completing this course, the reader will be able to: Identify those patients in both age groups who responded most favorably to first-line therapy with letrozole. Describe the advantages of first-line treatment with letrozole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a94a8e9450e009cdbe1d69ed0ae0d77
https://doi.org/10.1634/theoncologist.9-5-497
https://doi.org/10.1634/theoncologist.9-5-497
Autor:
Carsten Rose, O Vtoraya, R Thomas, F. Ben Ayed, JJ Caicedo, M Gershanovich, H. A. Chaudri-Ross, R. Lang, Anna Pluzanska, N Davidson, Scott A. Johnson, H Gervasio, G Manikhas, S Burdette-Radoux
Publikováno v:
European Journal of Cancer. 39:2318-2327
It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer. The objective of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dd6cb9f868cb2b9f94abe6825ac5e3b
https://doi.org/10.1016/s0959-8049(03)00630-0
https://doi.org/10.1016/s0959-8049(03)00630-0
Autor:
Laurence M. Demers, Allan Lipton, Walter P. Carney, Harold A. Harvey, H. A. Chaudri-Ross, Suhail M. Ali, C. Brady, P. Wyld, Kim Leitzel
Publikováno v:
Journal of Clinical Oncology. 21:1967-1972
Purpose: To determine the effect of elevated serum HER-2/neu on the response of metastatic breast cancer patients to an aromatase inhibitor versus an antiestrogen. Patients and Methods: Five hundred sixty-two estrogen receptor–positive metastatic b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::421c0ab534fd1acd3c83ce1e559061fa
https://doi.org/10.1200/jco.2003.09.098
https://doi.org/10.1200/jco.2003.09.098
Autor:
J. Eremin, Wolfgang Eiermann, J. Appfelstaedt, Louis Mauriac, M. Dugan, J. Vinholes, Vladimir Semiglazov, Antonio Llombart-Cussac, S. Paepke, H. A. Chaudri-Ross, M. Lassus, Mieke Borgs, Matthew J. Ellis
Publikováno v:
Annals of Oncology. 12:1527-1532
Background: A randomized, double-blind, multicenter study was conducted to compare the anti-tumor activity of letrozole vs. tamoxifen in postmenopausal women with ER and/or PgR positive primary untreated breast cancer. Patients and methods: Three hun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e3decaa6ab182dca32daf7d9d4753b7
https://doi.org/10.1023/a:1013128213451
https://doi.org/10.1023/a:1013128213451
Autor:
Henning T. Mouridsen, J. Arnold Verbeek, Yan Sun, Eeva Salminen, H. A. Chaudri-Ross, Fritz Jänicke, Dominique Becquart, Justus Apffelstaedt, Beatrix Staffler, Anna Pluzanska, Magdolna Dank, Robert S. Smith, Ramon Perez-Carrion, Margaret Dugan, Mikhail Gershanovich, Alain Monnier, Mercedes Lassus, Poonamalle P. Bapsy, Harm Sleeboom, Corrado Boni, Raymond Snyder
Publikováno v:
Journal of Clinical Oncology. 19:2596-2606
PURPOSE: To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer. PATIENTS AND METHODS: Nine hundred seven pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1db3f2ace9ebe08ee91f8d4c3a0473
https://doi.org/10.1200/jco.2001.19.10.2596
https://doi.org/10.1200/jco.2001.19.10.2596
Publikováno v:
Journal of Clinical Oncology. 20:876-878
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84622f7536f97354ab87c5eec9b44117
https://doi.org/10.1200/jco.2002.20.3.876
https://doi.org/10.1200/jco.2002.20.3.876
Autor:
Kim Leitzel, Wolfgang Hackl, Laurence M. Demers, H. A. Chaudri-Ross, Suhail M. Ali, Peter J. Hamer, Walter P. Carney, Dean B. Evans, Allan Lipton, Christopher Souder
Publikováno v:
Cancer. 107(10)
BACKGROUND. Epidermal growth factor receptor (EGFR, HER-1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme-linked imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626954a1ee1ae578eca074ff63633ccf
https://pubmed.ncbi.nlm.nih.gov/17048231
https://pubmed.ncbi.nlm.nih.gov/17048231